Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706886 | 1.00 | VEGFA (0.33) | VEGFA | |
| SCHEMBL31179930 | 0.84 | KIF11 (0.33) | — | |
| SCHEMBL18355357 | 0.84 | CA12 (0.33) | — | |
| SCHEMBL5839939 | 0.84 | KIF11 (0.33) | — | |
| SCHEMBL21436805 | 0.82 | EPAS1 (0.33) | VEGFA | |
| SCHEMBL30010666 | 0.81 | GPR3 (0.37) | VEGFA | |
| SCHEMBL3745580 | 0.81 | GPR3 (0.37) | VEGFA | |
| SCHEMBL23124958 | 0.78 | VEGFA (0.32) | VEGFA | |
| SCHEMBL758803 | 0.78 | VEGFA (0.30) | VEGFA | |
| SCHEMBL24611812 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174646-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-114641314-B | Method for treating or preventing chronic kidney disease | 日本烟草产业株式会社 | 2024-05-28 | — | — | CN | disclosed |
| EP-4342466-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | Japan Tobacco Inc. (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-111757877-B | Methyllactam ring compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2023-10-27 | — | — | CN | disclosed |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | JAPAN TOBACCO INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | JAPAN TOBACCO INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | JAPAN TOBACCO INC. (JP) | 2023-04-20 | — | — | US | disclosed |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | JAPAN TOBACCO INC. (JP) | 2023-04-20 | — | — | US | disclosed |
| EP-4026564-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | Japan Tobacco Inc. (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026562-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | Japan Tobacco Inc. (JP) | 2022-07-13 | — | — | EP | disclosed |
| US-20160039826-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL) QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| EP-2970293-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Respivert Limited (GB) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014140597-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| CN-101065370-B | 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG | 2012-11-14 | — | — | CN | disclosed |
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG | 2012-02-16 | — | — | US | disclosed |
| US-8076489-B2 | 3H-benzothiazol-2-one derivatives, for example, (R)-7-[2-(1,1-dimethyl-2-phenyl-ethylamino)-1-hydroxy-ethyl]-5-hydroxy-3H-benzothiazol-2-one; useful for treating conditions that are prevented or alleviated by activation of the beta 2-adrenoreceptor | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| EP-1819686-B1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2305659-A1 | 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| CN-101065370-A | 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2007-10-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039826-A1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL) QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PI4KB, PI4KA, IRAK3 | VEGFA 3310/4885 |
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | VEGFA 4412/4885 |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | SLC5A1, SLC5A2, REN | VEGFA 1105/4885 |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | ADRB2, ADRB1, ADRA2C | VEGFA 4412/4885 |
| US-20240174646-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC5A6 | VEGFA 3019/4885 |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | DPP4, SLC5A1, SLC5A2 | VEGFA 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.